A MULTICENTER STUDY OF 24 WEEKS OF DURATION, RANDOMIZED, DOUBLE-BLIND AND WITH SIMILAR ASPECT DRUGS, TO COMPARE THE EFFECTIVENESS OF AVANDIA FOR PROLONGED RELEASE (8 MG ONCE PER DAY) AND AVANDIA OF IMMEDIATE RELEASE (8 MG ONCE A DAY ) IN SUBJECTS WITH DIABETES MELLITUS OF TYPE 2.
Not Applicable
- Conditions
- -E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119
- Registration Number
- PER-052-04
- Lead Sponsor
- GLAXOSMITHKLINE BIOLOGICALS,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects with a clinical diagnosis of type 2 diabetes mellitus according to the ADA.
Male or female adults who are between 18 and 75 years of age at the time of selection.
Subjects that give their informed consent to participate.
Exclusion Criteria
Any clinically significant abnormality identified in the Screening Visit.
The use of any investigational drug within 30 days or 5 half-lives (whichever is longer) before administering the first dose of study medication
Anemia, defined by a hemoglobin concentration <11 g / dL for men or <10 g / dL for women.
The subject has a hemoglobinopathy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method